Literature DB >> 19730726

Subsequent Immunological Mechanisms.

A G Tsamaloukas.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19730726      PMCID: PMC2735840          DOI: 10.3238/arztebl.2009.0526a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

Authors:  Wen-Kai Weng; Ronald Levy
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

2.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

Authors:  Antonino Musolino; Nadia Naldi; Beatrice Bortesi; Debora Pezzuolo; Marzia Capelletti; Gabriele Missale; Diletta Laccabue; Alessandro Zerbini; Roberta Camisa; Giancarlo Bisagni; Tauro Maria Neri; Andrea Ardizzoni
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

Review 3.  The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.

Authors:  Sebastian Stintzing; Volker Heinemann; Nicolas Moosmann; Wolfgang Hiddemann; Andreas Jung; Thomas Kirchner
Journal:  Dtsch Arztebl Int       Date:  2009-03-20       Impact factor: 5.594

4.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Authors:  Frédéric Bibeau; Evelyne Lopez-Crapez; Frédéric Di Fiore; Simon Thezenas; Marc Ychou; France Blanchard; Aude Lamy; Frédérique Penault-Llorca; Thierry Frébourg; Pierre Michel; Jean-Christophe Sabourin; Florence Boissière-Michot
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.